Athira Pharma Advances ATH-1105 Clinical Trial for ALS Treatment
Tuesday, 11 June 2024, 08:20
Athira Pharma Progresses in Phase 1 Clinical Trial of ATH-1105 for ALS Treatment
Athira Pharma has achieved a milestone by completing the first cohort in the Phase 1 clinical trial of ATH-1105, a small molecule drug candidate aimed at treating Amyotrophic Lateral Sclerosis (ALS).
Key Highlights:
- Advancement: Progress made in the clinical trial marks a significant step towards developing a potential treatment for ALS.
- Promising Candidate: ATH-1105, an oral small molecule drug, shows promise in the treatment of ALS.
- Impact: Positive results from the trial could lead to improved therapeutic options for ALS patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.